StockData
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Medpace Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 22, 2026
$619.66+1.19 (+0.19%)

Close on Oct 19, 2026

Market cap
$17.69B
P/E (TTM)
36.3
Dividend yield
–

Earnings

Next report expected Oct 21, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 22, 2026After market close$707.30M$4.25–
Q1 FY2026
Ended Mar 31, 2026
Apr 22, 2026After market close$706.60M$4.28–
Q4 FY2025
Ended Dec 31, 2025
Feb 9, 2026After market close$708.50M$4.67–
Q3 FY2025
Ended Sep 30, 2025
Oct 22, 2025After market close$659.90M$3.86–
Q2 FY2025
Ended Jun 30, 2025
Jul 21, 2025After market close$603.30M$3.10–
Q1 FY2025
Ended Mar 31, 2025
Apr 21, 2025After market close$558.60M$3.67–
Q4 FY2024
Ended Dec 31, 2024
Feb 10, 2025After market close$536.60M$3.67–
Q3 FY2024
Ended Sep 30, 2024
Oct 21, 2024After market close$533.30M$3.01–
Q2 FY2024
Ended Jun 30, 2024
Jul 22, 2024After market close$528.10M$2.75–
Q1 FY2024
Ended Mar 31, 2024
Apr 22, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 12, 2024After market close–––

Company guidance

Outlook given with results on Jul 22, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
EBITDAnon-GAAPfull year 2026$618.00M to $642.00MRaised
diluted earnings per share (GAAP)GAAP2026$17.25 to $17.95Raised
diluted weighted average shares outstandingfull year 202628.6Lowered
tax ratefull year 202619% to 19.5%Lowered
interest incomefull year 2026$21.10MLowered
GAAP net incomeGAAPfull year 2026$494.00M to $514.00MRaised
revenueGAAP2026$2.81B to $2.89BNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Medpace filed with the SEC